A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and NabPaclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma

Brief description of study

This study is investigating the combination of CA-4948 and gemcitabine/nab-paclitaxel chemotherapy to find the highest dose that patients can take who have adenocarcinoma of the pancreas. To do this, patients will go through a dose escalation phase and be treated in small groups at different doses. The dose escalation phase follows a special design called BOIN (way of using numbers and data to figure out the right amount of medicine to give to patients in the study), which helps determine the maximum tolerated dose with minimal dose-limiting side effects to make sure the dose is safe and effective.


Clinical Study Identifier: s23-00370
Principal Investigator: Kristen Spencer.
Other Investigators: Daniel J Becker, Marta Wioleta Wronska, Jennifer Chuy, Keriann M Scavone, Nina Beri, Paul E. Oberstein, Michael Shusterman, Rafael Winograd, Shun Yu, Alexander A Hindenburg.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.